Search

Your search keyword '"Lawrence E. Feldman"' showing total 15 results
Start Over Author "Lawrence E. Feldman" Search Limiters Full Text
15 results on '"Lawrence E. Feldman"'

1. Elevated serum CA 19–9 level mimicking pancreaticobiliary carcinoma from a hepatic abscess: case report and literature review

Author

Shaurya Dhingra, Puneet Raman, Taylor Ramsaroop, Isaiah Harrison, Tova Bergsten, Erin Nusbaum, and Lawrence E. Feldman

Subjects
CA 19–9, tumor marker, hepatic abscess, hepatobiliary, hepatology, Medicine (General), R5-920
Abstract

Serum levels of the tumor marker CA 19–9 are widely utilized in the diagnosis and monitoring pancreatic and biliary malignancies. However, serum levels of CA 19–9 have also been reportedly elevated in non-malignant conditions. Here, we present the rare case of a 65-year-old woman with a history of gallbladder malignancy who was found to have a new hepatic lesion on surveillance CT with an associated elevation in CA 19–9 to 5,866 U/mL. Drainage of the lesion and treatment with antibiotics resulted in a rapid decline in CA 19–9 levels, indicating that the elevation in CA 19–9 was due to a benign hepatic lesion. We review eight similar reported cases of CA 19–9 elevations due to benign hepatic abscesses, thereby highlighting a need to interpret the tumor marker with caution.

Published
2025
Full Text
View/download PDF

2. Brief Report: Precision Language and Deletion of the 'S' Word

Author

Ciara Lockstadt, MD, Mary M. Pasquinelli, DNP, Jill Feldman, MD, Jamie L. Studts, PhD, Jamie S. Ostroff, PhD, Li Liu, PhD, Ella A. Kazerooni, MD, Robert A. Smith, PhD, Lisa Carter-Bawa, PhD, and Lawrence E. Feldman, MD

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: In 2021, the International Association for the Study of Lung Cancer (IASLC) published the IASLC Language Guide as guidance on preferred language and phrasing in oral and written communications, including presentations at conferences. This study analyzed presentations from the 2022 IASLC World Conference on Lung Cancer (WCLC) one year after implementation of the Language Guide to identify adoption rates of non-stigmatizing language and to determine correlations with presenter characteristics. Methods: We downloaded 522 slide presentations from the IASLC WCLC 2022 conference attendee portal. We searched each presentation, including images, for discussion of tobacco use and the use of the term “smoker,” which is an indicator of stigmatizing language. We conducted internet searches to gather presenters’ stated home continent, sex, specialty, and professional degree. Results: Of 177 presentations that discussed smoking status, 77 presenters used non-stigmatizing language, whereas 100 presenters used the stigmatizing term “smoker.” Male MDs and female PhDs and non-medicine subspecialties and advocates were more likely to use non-stigmatizing language. Conclusions: Encouragingly, only after one year post-release of the Language Guide, more than one-third of the presenters at the WCLC used non-stigmatizing language. This finding represents a step toward improving respectful and inclusive language surrounding smoking within the thoracic oncology community.

Published
2025
Full Text
View/download PDF

3. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer

Author

Alexandre F. Aissa, Abul B. M. M. K. Islam, Majd M. Ariss, Cammille C. Go, Alexandra E. Rader, Ryan D. Conrardy, Alexa M. Gajda, Carlota Rubio-Perez, Klara Valyi-Nagy, Mary Pasquinelli, Lawrence E. Feldman, Stefan J. Green, Nuria Lopez-Bigas, Maxim V. Frolov, and Elizaveta V. Benevolenskaya

Subjects
Science
Abstract

It has been proposed that resistance to targeted therapies in non-small cell lung carcinoma (NSCLC) is due to a nonhomogeneous cell population. Here the authors analyse preclinical NSCLC models using single-cell RNA-seq and identify drug tolerant cell states and subpopulations, as well as associated genes.

Published
2021
Full Text
View/download PDF

4. Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria—Reducing Race Disparities

Author

Mary M. Pasquinelli, DNP, Martin C. Tammemägi, PhD, Kevin L. Kovitz, MD, Marianne L. Durham, DNP, Zanë Deliu, MS, Kayleigh Rygalski, BS, Li Liu, PhD, Matthew Koshy, MD, Patricia Finn, MD, and Lawrence E. Feldman, MD

Subjects
Lung cancer screening, PLCOm2012 risk prediction model, Race disparities, African American, United States Preventive Services Task Force, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: Eligibility criteria for lung cancer screening based solely on age and smoking history are less sensitive than validated risk prediction models. The U.S. Preventive Services Task Force (USPSTF) has proposed new guidelines to improve the sensitivity for selecting high-risk individuals and to decrease race disparity. In this retrospective study, termed the Chicago Race Eligibility for Screening Cohort, we compare the sensitivity of the proposed USPSTF2020 criteria versus the PLCOm2012 risk prediction model for selecting a racially diverse lung cancer population with a smoking history for lung cancer screening. Methods: This Chicago Race Eligibility for Screening Cohort study applies the PLCOm2012 model with a risk threshold of 1.0%/6 years and the USPSTF2020 criteria (age 50–80 y, pack-years ≥ 20 y, quit-years ≤ 15 y) to 883 individuals with a smoking history diagnosed with having lung cancer. Results: The PLCOm2012 was more sensitive than the USPSTF2020 overall (79.1% versus 68.6%, p < 0.0001) in White (81.5% versus 75.4%, p = 0.029) and in African American (82.8% versus 70.6% p < 0.0001) individuals. Of the total cohort, 254 (28.8%) would not have qualified owing to less than 20 pack-years, quit-time of more than 15 years, and age less than 50 years. Of these 254 cases, 40% would have qualified by the PLCOm2012 model. For the 20 pack-year criterion, of the 497 African American individuals, 19.3% did not meet this criterion, and of these, an additional 31.3% would have qualified by the PLCOm2012 model (p = 0.002). Conclusions: Although more sensitive than USPSTF2013, the proposed USPSTF2020 draft guidelines still have a race disparity in eligibility for screening. This study provides “real world” evidence that use of the PLCOm2012 risk prediction model eliminates this race disparity.

Published
2021
Full Text
View/download PDF

6. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

Author

Gayathri Nagaraj, Shaveta Vinayak, Ali Raza Khaki, Tianyi Sun, Nicole M Kuderer, David M Aboulafia, Jared D Acoba, Joy Awosika, Ziad Bakouny, Nicole B Balmaceda, Ting Bao, Babar Bashir, Stephanie Berg, Mehmet A Bilen, Poorva Bindal, Sibel Blau, Brianne E Bodin, Hala T Borno, Cecilia Castellano, Horyun Choi, John Deeken, Aakash Desai, Natasha Edwin, Lawrence E Feldman, Daniel B Flora, Christopher R Friese, Matthew D Galsky, Cyndi J Gonzalez, Petros Grivas, Shilpa Gupta, Marcy Haynam, Hannah Heilman, Dawn L Hershman, Clara Hwang, Chinmay Jani, Sachin R Jhawar, Monika Joshi, Virginia Kaklamani, Elizabeth J Klein, Natalie Knox, Vadim S Koshkin, Amit A Kulkarni, Daniel H Kwon, Chris Labaki, Philip E Lammers, Kate I Lathrop, Mark A Lewis, Xuanyi Li, Gilbert de Lima Lopes, Gary H Lyman, Della F Makower, Abdul-Hai Mansoor, Merry-Jennifer Markham, Sandeep H Mashru, Rana R McKay, Ian Messing, Vasil Mico, Rajani Nadkarni, Swathi Namburi, Ryan H Nguyen, Taylor Kristian Nonato, Tracey Lynn O'Connor, Orestis A Panagiotou, Kyu Park, Jaymin M Patel, Kanishka GopikaBimal Patel, Jeffrey Peppercorn, Hyma Polimera, Matthew Puc, Yuan James Rao, Pedram Razavi, Sonya A Reid, Jonathan W Riess, Donna R Rivera, Mark Robson, Suzanne J Rose, Atlantis D Russ, Lidia Schapira, Pankil K Shah, M Kelly Shanahan, Lauren C Shapiro, Melissa Smits, Daniel G Stover, Mitrianna Streckfuss, Lisa Tachiki, Michael A Thompson, Sara M Tolaney, Lisa B Weissmann, Grace Wilson, Michael T Wotman, Elizabeth M Wulff-Burchfield, Sanjay Mishra, Benjamin French, Jeremy L Warner, Maryam B Lustberg, Melissa K Accordino, Dimpy P Shah, and On behalf of the COVID-19 and Cancer Consortium

Subjects
breast cancer, SARS-CoV-2, COVID-19, racial inequities, oncology, pandemic, Medicine, Science, Biology (General), QH301-705.5
Abstract

Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity. Results: 1383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32–1.67]); Black patients (aOR 1.74; 95 CI 1.24–2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70–6.79) and Other (aOR 2.97; 95 CI 1.71–5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83–12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63–3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20–2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66–3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89–22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort was 9% and 37%, respectively however, it varied according to the BC disease status. Conclusions: Using one of the largest registries on cancer and COVID-19, we identified patient and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to non-Hispanic White patients. Funding: This study was partly supported by National Cancer Institute grant number P30 CA068485 to Tianyi Sun, Sanjay Mishra, Benjamin French, Jeremy L Warner; P30-CA046592 to Christopher R Friese; P30 CA023100 for Rana R McKay; P30-CA054174 for Pankil K Shah and Dimpy P Shah; KL2 TR002646 for Pankil Shah and the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE) and P30-CA054174 for Dimpy P Shah. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. Clinical trial number: CCC19 registry is registered on ClinicalTrials.gov, NCT04354701.

Published
2023
Full Text
View/download PDF

7. Data from Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer

Author

Alicia Hulbert, James G. Herman, Malcolm V. Brock, Robert A. Winn, Enrico Benedetti, Ignacio Jusue-Torres, Tza-Huei Wang, Malek G. Massad, Lawrence E. Feldman, Mary Pasquinelli, Christian Ascoli, Ron C. Gaba, Odile David, Klara Valyi-Nagy, Nicole Gastala, Kyla Holmes, Tomoaki Ito, Chen Chen, Kristen Rodgers, Anastasia Kottorou, Cassandra Villani, Apurva Mallisetty, Julio Ricarte Filho, and Bin Liu

Abstract

Purpose:Low-dose CT screening can reduce lung cancer–related mortality. However, CT screening has an FDR of nearly 96%. We sought to assess whether urine samples can be a source for DNA methylation–based detection of non–small cell lung cancer (NSCLC).Experimental Design:This nested case–control study of subjects with suspicious nodules on CT imaging obtained plasma and urine samples preoperatively. Cases (n = 74) had pathologic confirmation of NSCLC. Controls (n = 27) had a noncancer diagnosis. We detected promoter methylation in plasma and urine samples using methylation on beads and quantitative methylation–specific real-time PCR for cancer-specific genes (CDO1, TAC1, HOXA7, HOXA9, SOX17, and ZFP42).Results:DNA methylation at cancer-specific loci was detected in both plasma and urine, and was more frequent in patients with cancer compared with controls for all six genes in plasma and in CDO1, TAC1, HOXA9, and SOX17 in urine. Univariate and multivariate logistic regression analysis showed that methylation detection in each one of six genes in plasma and CDO1, TAC1, HOXA9, and SOX17 in urine were significantly associated with the diagnosis of NSCLC, independent of age, race, and smoking pack-years. When methylation was detected for three or more genes in both plasma and urine, the sensitivity and specificity for lung cancer diagnosis were 73% and 92%, respectively.Conclusions:DNA methylation–based biomarkers in plasma and urine could be useful as an adjunct to CT screening to guide decision-making regarding further invasive procedures in patients with pulmonary nodules.

Published
2023
Full Text
View/download PDF

8. Supplementary Table S2 from Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer

Author

Alicia Hulbert, James G. Herman, Malcolm V. Brock, Robert A. Winn, Enrico Benedetti, Ignacio Jusue-Torres, Tza-Huei Wang, Malek G. Massad, Lawrence E. Feldman, Mary Pasquinelli, Christian Ascoli, Ron C. Gaba, Odile David, Klara Valyi-Nagy, Nicole Gastala, Kyla Holmes, Tomoaki Ito, Chen Chen, Kristen Rodgers, Anastasia Kottorou, Cassandra Villani, Apurva Mallisetty, Julio Ricarte Filho, and Bin Liu

Abstract

Univariate logistic regression analysis for risk of having NSCLC.

Published
2023
Full Text
View/download PDF

9. Figure S4 from Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer

Author

Alicia Hulbert, James G. Herman, Malcolm V. Brock, Robert A. Winn, Enrico Benedetti, Ignacio Jusue-Torres, Tza-Huei Wang, Malek G. Massad, Lawrence E. Feldman, Mary Pasquinelli, Christian Ascoli, Ron C. Gaba, Odile David, Klara Valyi-Nagy, Nicole Gastala, Kyla Holmes, Tomoaki Ito, Chen Chen, Kristen Rodgers, Anastasia Kottorou, Cassandra Villani, Apurva Mallisetty, Julio Ricarte Filho, and Bin Liu

Abstract

Figure S4

Published
2023
Full Text
View/download PDF

10. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Dimitrios Farmakiotis, Susie Owenby, Arturo Loaiza-Bonilla, Mansi R. Shah, Matthew Puc, Vadim S. Koshkin, Ahmad Daher, Prakash Peddi, Cameron Rink, Heloisa P. Soares, Eneida R. Nemecek, Mehmet Asim Bilen, Sanjay Mishra, Lidia Schapira, Amit Verma, Ali Raza Khaki, Chih-Yuan Hsu, Sandy DiLullo, Mark Bonnen, Jeanna Knoble, Carla Casulo, Umit Topaloglu, Jorge A. Garcia, Geoffrey Shouse, Praveen Vikas, Clarke A. Low, Archana Ajmera, George D. Demetri, Leyre Zubiri, Grace Glace, Shannon K. McWeeney, Susan Yackzan, Pamela C Egan, Rachel P. Rosovsky, Salvatore Del Prete, Anthony P. Gulati, Lane R. Rosen, Andy Futreal, Merry Jennifer Markham, Sabitha Prabhakaran, Alicia K. Morgans, Sarah Nagle, Lisa Weissmann, Albert C. Yeh, Ziad Bakouny, Stephanie Berg, David Gill, Marcus Messmer, Ryan Nguyen, Terence Duane Rhodes, Vikram M. Narayan, Matthew D. Galsky, Arielle Elkrief, Lori J. Rosenstein, Roy S. Herbst, Justin Shaya, Thorvardur R. Halfdanarson, Douglas B. Johnson, Orestis A. Panagiotou, Sanjay G. Revankar, Toni K. Choueiri, Yu Shyr, Fiona Busser, Kaitlin M. Kelleher, Nicole M. Kuderer, Paul L. Weinstein, Anup Kasi, Grace Shaw, Adam J. Olszewski, Catherine Curran, Samuel M. Rubinstein, Angelo Cabal, Michael H. Bar, John F. Deeken, Vivek Subbiah, Abdul Hai Mansoor, Hina Khan, Rana R. McKay, Catherine Stratton, Saurabh Dahiya, Marc A. Rovito, John Philip, Sanjay Shete, Oscar K. Serrano, Julie Fu, Daniel W. Bowles, Candice Schwartz, Tian Zhang, Pier Vitale Nuzzo, Eric H. Bernicker, Wenxin Xu, Genevieve M. Boland, Sarah Wall, Babar Bashir, Solange Peters, Neeta K. Venepalli, Sandeep H. Mashru, William A. Wood, Anne H. Angevine, Mary F. Mulcahy, Gilberto Lopes, Justin F. Gainor, Jessica Hawley, Monika Joshi, Christopher R. Friese, Navid Hafez, Heather H. Nelson, Gregory J. Riely, Jordan Kharofa, Nilo Azad, Chintan Shah, Gerald Batist, Mary Salazar, Rosemary Zacks, Alice Zhou, Lawrence E. Feldman, Paul Fu, Gary H. Lyman, Nathaniel Bouganim, John A. Steinharter, Shilpa Gupta, Matthias Weiss, Peter Paul Yu, Susan Van Loon, Jamie Stratton, Karen Vega-Luna, Tyler Masters, Christopher Lemmon, Aakash Desai, Bryan A. Faller, Jessica M. Clement, Zhuoer Xie, Keith Stockerl-Goldstein, Corrie A. Painter, Gabrielle Bouchard, Rulla M. Tamimi, Daruka Mahadevan, Rimma Belenkaya, Jill S. Barnholtz-Sloan, Jarushka Naidoo, Amelie G. Ramirez, Philip E. Lammers, Elizabeth A. Griffiths, Michael J. Gurley, X. Li, Jonathan Riess, Syed A. Ahmad, Daniel Blake Flora, Salma K. Jabbour, Jared D. Acoba, Neeraj Agarwal, Ang Li, Sarah Mushtaq, Firas Wehbe, Tanios Bekaii-Saab, Donald C. Vinh, Emily Hsu, Ryan Monahan, Petros Grivas, Harry Menon, John M. Nakayama, Janice M. Mehnert, Elizabeth Marie Wulff-Burchfield, Sara Matar, Paul E. Oberstein, Mary M. Pasquinelli, Axel Grothey, Jack West, John C. Leighton, Dawn L. Hershman, Leslie A. Fecher, Aditya Bardia, Sumit A. Shah, Barbara Logan, Kerry L. Reynolds, Michael A. Thompson, Robert L. Rice, Erin Cook, Trisha Wise-Draper, Christine Bestvina, Daniel Castellano, Paolo Caimi, K. M.Steve Lo, Ruben A. Mesa, Maheen Z. Abidi, Alvaro G. Menendez, Daniel G. Stover, Colleen Lewis, Bertrand Routy, Deborah B. Doroshow, Carmen C. Solorzano, M. Wasif Saif, Rohit Bishnoi, Michael Glover, David D. Chism, Briana Barrow, Christopher McNair, Dimpy P. Shah, Erin A. Gillaspie, Andrea J. Zimmer, Andrew Schmidt, Jessica K. Altman, Michelle Marcum, Rawad Elias, Balazs Halmos, Karen Stauffer, Gayathri Nagaraj, Ardaman Shergill, Mark E. Dailey, Catherine Handy Marshall, Pramod K. Srivastava, Shuchi Gulati, Alokkumar Jha, Mateo Bover Larroya, Mark A. Lewis, Young Soo Rho, James L. Chen, Eli Van Allen, Julie Tsu Yu Wu, Antonio Giordano, Amit Kulkarni, Joerg Rathmann, Donna R. Rivera, Narjust Duma, Maryam B. Lustberg, Theresa M. Carducci, Jeremy L. Warner, Elizabeth Robilotti, Patricia LoRusso, Rohit Jain, Amit Sanyal, Nizar M. Tannir, Kent Hoskins, Nathan A. Pennell, Brian I. Rini, Suki Subbiah, COVID-19 and Cancer Consortium, Abidi, M., Acoba, J.D., Agarwal, N., Ahmad, S., Ajmera, A., Altman, J., Angevine, A.H., Azad, N., Bar, M.H., Bardia, A., Barnholtz-Sloan, J., Barrow, B., Bashir, B., Belenkaya, R., Berg, S., Bernicker, E.H., Bestvina, C., Bishnoi, R., Boland, G., Bonnen, M., Bouchard, G., Bowles, D.W., Busser, F., Cabal, A., Caimi, P., Carducci, T., Casulo, C., Chen, J.L., Clement, J.M., Chism, D., Cook, E., Curran, C., Daher, A., Dailey, M., Dahiya, S., Deeken, J., Demetri, G.D., DiLullo, S., Duma, N., Elias, R., Faller, B., Fecher, L.A., Feldman, L.E., Friese, C.R., Fu, P., Fu, J., Futreal, A., Gainor, J., Garcia, J., Gill, D.M., Gillaspie, E.A., Giordano, A., Glace, M.G., Grothey, A., Gulati, S., Gurley, M., Halmos, B., Herbst, R., Hershman, D., Hoskins, K., Jain, R.K., Jabbour, S., Jha, A., Johnson, D.B., Joshi, M., Kelleher, K., Kharofa, J., Khan, H., Knoble, J., Koshkin, V.S., Kulkarni, A.A., Lammers, P.E., Leighton, J.C., Lewis, M.A., Li, X., Li, A., Lo, KMS, Loaiza-Bonilla, A., LoRusso, P., Low, C.A., Lustberg, M.B., Mahadevan, D., Mansoor, A.H., Marcum, M., Markham, M.J., Handy Marshall, C., Mashru, S.H., Matar, S., McNair, C., McWeeney, S., Mehnert, J.M., Menendez, A., Menon, H., Messmer, M., Monahan, R., Mushtaq, S., Nagaraj, G., Nagle, S., Naidoo, J., Nakayama, J.M., Narayan, V., Nelson, H.H., Nemecek, E.R., Nguyen, R., Nuzzo, P.V., Oberstein, P.E., Olszewski, A.J., Owenby, S., Pasquinelli, M.M., Philip, J., Prabhakaran, S., Puc, M., Ramirez, A., Rathmann, J., Revankar, S.G., Rho, Y.S., Rhodes, T.D., Rice, R.L., Riely, G.J., Riess, J., Rink, C., Robilotti, E.V., Rosenstein, L., Routy, B., Rovito, M.A., Saif, M.W., Sanyal, A., Schapira, L., Schwartz, C., Serrano, O., Shah, M., Shah, C., Shaw, G., Shergill, A., Shouse, G., Soares, H.P., Solorzano, C.C., Srivastava, P.K., Stauffer, K., Stover, D.G., Stratton, J., Stratton, C., Subbiah, V., Tamimi, R., Tannir, N.M., Topaloglu, U., Van Allen, E., Van Loon, S., Vega-Luna, K., Venepalli, N., Verma, A.K., Vikas, P., Wall, S., Weinstein, P.L., Weiss, M., Wise-Draper, T., Wood, W.A., Xu, W.V., Yackzan, S., Zacks, R., Zhang, T., Zimmer, A.J., and West, J.

Subjects
Prognostic variable, medicine.medical_specialty, business.industry, Cancer, General Medicine, Odds ratio, Aged, Antiviral Agents/therapeutic use, Azithromycin/therapeutic use, Betacoronavirus, Cause of Death, Comorbidity, Coronavirus Infections/drug therapy, Coronavirus Infections/epidemiology, Coronavirus Infections/mortality, Databases, Factual, Female, Humans, Hydroxychloroquine/therapeutic use, Male, Middle Aged, Neoplasms/epidemiology, Neoplasms/mortality, Neoplasms/therapy, Pandemics, Pneumonia, Viral/drug therapy, Pneumonia, Viral/epidemiology, Pneumonia, Viral/mortality, Prognosis, Risk Factors, 030204 cardiovascular system & hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Cohort, Clinical endpoint, Medicine, 030212 general & internal medicine, business, Cause of death, Cohort study
Abstract

Summary Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing. Findings Of 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57–76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53–2·21), male sex (1·63, 1·07–2·48), smoking status (former smoker vs never smoked: 1·60, 1·03–2·47), number of comorbidities (two vs none: 4·50, 1·33–15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11–7·18), active cancer (progressing vs remission: 5·20, 2·77–9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79–4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07–0·84) or the US-Midwest (0·50, 0·28–0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality. Interpretation Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments. Funding American Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.

Published
2020
Full Text
View/download PDF

11. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study

Author

Gowri Satyanarayana, Kyle T Enriquez, Tianyi Sun, Elizabeth J Klein, Maheen Abidi, Shailesh M Advani, Joy Awosika, Ziad Bakouny, Babar Bashir, Stephanie Berg, Marilia Bernardes, Pamela C Egan, Arielle Elkrief, Lawrence E Feldman, Christopher R Friese, Shipra Goel, Cyndi Gonzalez Gomez, Keith L Grant, Elizabeth A Griffiths, Shuchi Gulati, Shilpa Gupta, Clara Hwang, Jayanshu Jain, Chinmay Jani, Anna Kaltsas, Anup Kasi, Hina Khan, Natalie Knox, Vadim S Koshkin, Daniel H Kwon, Chris Labaki, Gary H Lyman, Rana R McKay, Christopher McNair, Gayathri Nagaraj, Elizabeth S Nakasone, Ryan Nguyen, Taylor K Nonato, Adam J Olszewski, Orestis A Panagiotou, Matthew Puc, Pedram Razavi, Elizabeth V Robilotti, Miriam Santos-Dutra, Andrew L Schmidt, Dimpy P Shah, Sumit A Shah, Kendra Vieira, Lisa B Weissmann, Trisha M Wise-Draper, Ulysses Wu, Julie Tsu-Yu Wu, Toni K Choueiri, Sanjay Mishra, Jeremy L Warner, Benjamin French, and Dimitrios Farmakiotis

Subjects
viral infections, Prevention, COVID-19, CAPA, mucormycoses, Emerging Infectious Diseases, Good Health and Well Being, Infectious Diseases, bacterial infections, Oncology, Clinical Research, 2.2 Factors relating to the physical environment, Aetiology, Infection, Lung, Cancer
Abstract

Background The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronavirus disease 2019 (COVID-19), a high-risk group for coinfection. Methods We included adult (≥18 years) patients with active or prior hematologic or invasive solid malignancies and laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, using data from the COVID-19 and Cancer Consortium (CCC19, NCT04354701). We captured coinfections within ±2 weeks from diagnosis of COVID-19, identified factors cross-sectionally associated with risk of coinfection, and quantified the association of coinfections with 30-day mortality. Results Among 8765 patients (hospitalized or not; median age, 65 years; 47.4% male), 16.6% developed coinfections: 12.1% bacterial, 2.1% viral, 0.9% fungal. An additional 6.4% only had clinical diagnosis of a coinfection. The adjusted risk of any coinfection was positively associated with age >50 years, male sex, cardiovascular, pulmonary, and renal comorbidities, diabetes, hematologic malignancy, multiple malignancies, Eastern Cooperative Oncology Group Performance Status, progressing cancer, recent cytotoxic chemotherapy, and baseline corticosteroids; the adjusted risk of superinfection was positively associated with tocilizumab administration. Among hospitalized patients, high neutrophil count and C-reactive protein were positively associated with bacterial coinfection risk, and high or low neutrophil count with fungal coinfection risk. Adjusted mortality rates were significantly higher among patients with bacterial (odds ratio [OR], 1.61; 95% CI, 1.33–1.95) and fungal (OR, 2.20; 95% CI, 1.28–3.76) coinfections. Conclusions Viral and fungal coinfections are infrequent among patients with cancer and COVID-19, with the latter associated with very high mortality rates. Clinical and laboratory parameters can be used to guide early empiric antimicrobial therapy, which may improve clinical outcomes.

Published
2022
Full Text
View/download PDF

12. Abstract LB118: CEACAM7 as epigenetic prognostic marker in African Americans with lung adenocarcinoma

Author

Richies Tiv, Ignacio Jusue-Torres, Apurva Mallisetty, Leglys Contreras-Vargas, Ludmila Danilova, Lawrence E. Feldman, and Alicia Hulbert

Subjects
Cancer Research, Oncology
Abstract

Background and Objectives of the Study: For the past several decades, lung cancer has had amongst the highest cancer incidence and mortality rates across the world. In the United States, African American (AA) individuals carry a disproportionate share of the lung cancer burden, with higher incidence, later-stage diagnosis, and poorer 5-year overall survival rate when compared with that of Whites. However, there is yet to be a race-specific biomarker for lung cancer. Most genomic data continue to include a small proportion of AA individuals, further contributing to the racial health disparity. Thus, the goal of our study was to conduct a genome-wide analysis to identify lung cancer biomarkers specific for AA individuals, to understand the role that these biomarkers play in overall survival, and to discover how epigenetic modulations may impact outcomes by race. Methods: We utilized clinical and genomic data from The Cancer Genome Atlas (TCGA) for lung adenocarcinoma (LUAD). We conducted a differential expression analysis to identify the differentially expressed genes (DEGs) amongst AA individuals compared with Whites with LUAD. Two-tailed log rank tests with univariate and multivariate Cox proportional hazard models adjusted by age, gender, prior malignancy and stage were used to analyze overall survival for mRNA expression and DNA methylation for each racial subgroup. We investigated the epigenetic modifications that are correlated with the expression of the DEGs that play a significant role in the survival of AA individuals with lung cancer. Results: CEACAM7 was the single gene that was both differentially expressed in AA individuals compared to Whites with LUAD and that had an impact on LUAD survival. CEACAM7 RNA expression showed trend towards significant direct correlation with LUAD stage in AA individuals but not for Whites. High RNA expression of CEACAM7 was associated with shorter median survival (P Conclusion: This TCGA study suggests that the expression of CEACAM7 and its associated DNA methylation may play an important role in the survival of AA individuals with LUAD but not for Whites. Further studies are necessary to understand the mechanics of how the epigenetic regulation of CEACAM7 is associated with survival in AA individuals with LUAD and to identify new possible therapeutic targets. Citation Format: Richies Tiv, Ignacio Jusue-Torres, Apurva Mallisetty, Leglys Contreras-Vargas, Ludmila Danilova, Lawrence E. Feldman, Alicia Hulbert. CEACAM7 as epigenetic prognostic marker in African Americans with lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB118.

Published
2022
Full Text
View/download PDF

13. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Author

Sarah Wall, Babar Bashir, Toni K. Choueiri, Salvatore Del Prete, Grace Shaw, Solange Peters, Catherine Curran, Navid Hafez, Nathaniel Bouganim, Sarah Nagle, Julie Tsu-Yu Wu, Jared D. Acoba, Vaibhav Kumar, Gabrielle Bouchard, Lisa Weissmann, Hagen F. Kennecke, Tian Zhang, Manmeet Ahluwalia, Sanjay Goel, Samuel M. Rubinstein, Daruka Mahadevan, Elizabeth A. Griffiths, Destry J. Elms, Michael J. Gurley, Arturo Loaiza-Bonilla, Suki Subbiah, Gilberto Lopes, Lisa Tachiki, David M. Aboulafia, Kent Hoskins, Daniel W. Bowles, Sandeep H. Mashru, Matthew Puc, Prakash Peddi, Nathan A. Pennell, Stephen V. Liu, Justin F. Gainor, Ali Raza Khaki, Rebecca L. Zon, Matthew D Tucker, Amanda Nizam, Bryan A. Faller, Deborah B. Doroshow, Nitin Ohri, Brian I. Rini, Abdul-Hai Mansoor, Sachin R. Jhawar, George D. Demetri, Catherine Stratton, Eliezer M. Van Allen, Praveen Vikas, Alvaro G. Menendez, Amelie G. Ramirez, Jonathan M. Loree, Divaya Bhutani, Clarke A. Low, Anju Nohria, Melissa K. Accordino, Rohit Bishnoi, Pamela C Egan, Rachel P. Rosovsky, Julie C. Fu, Fiona Busser, Orestis A. Panagiotou, Aditya Bardia, Peter Paul Yu, Susan Van Loon, Genevieve M. Boland, Douglas B. Johnson, Anup Kasi, Barbara Logan, Alice Zhou, Matthew D. Galsky, Arielle Elkrief, Mary Salazar, Rosemary Zacks, Carmen C. Solorzano, Andrew Schmidt, Paolo Caimi, Zhuoer Xie, Michael T. Schweizer, Briana Barrow McCollough, Jessica K. Altman, Christopher McNair, Cassandra Hennessy, Angelo Cabal, Qamar Ul Zaman, Alex Cheng, Keith Stockerl-Goldstein, John C. Leighton, Joshua D. Palmer, Scott J. Dawsey, Deepak Ravindranathan, Jonathan Riess, Miriam Santos Dutra, Daniel Blake Flora, Aakash Desai, Rana R. McKay, Ruben A. Mesa, Maheen Z. Abidi, Cathleen Park, Jill S. Barnholtz-Sloan, Erin Cook, Trisha Wise-Draper, Shannon K. McWeeney, Donald C. Vinh, Clara Hwang, Stephanie Berg, Leyre Zubiri, Daniel G. Stover, Michelle Marcum, Sarah Mushtaq, Wilhelmina D. Cabalona, Eyob Tadesse, Kanishka G. Patel, Ryan Monahan, Ziad Bakouny, Pankil Shah, David Gill, Terence Duane Rhodes, Marc A. Rovito, Chih-Yuan Hsu, Elizabeth T. Loggers, Shilpa Gupta, Susie Owenby, Benjamin A. Gartrell, David D. Chism, Neeta K. Venepalli, Punita Grover, Adam J. Olszewski, Sonya A. Reid, Firas Wehbe, Omar Butt, Emily Hsu, Poorva Bindal, Paul L. Weinstein, Jessica Hawley, Tanya M. Wildes, Subha Madhavan, Claire Hoppenot, Margaret E. Gatti-Mays, Huili Zhu, Michael Glover, Rawad Elias, Elizabeth S. Nakasone, Heather H. Nelson, Gerald Batist, Gary H. Lyman, John F. Deeken, Michael H. Bar, Pamela Bohachek, Benjamin French, Mark A. Lewis, Daniel J. Hausrath, Mary F. Mulcahy, X. Li, David A. Slosky, Michael J. Wagner, Nicole Williams, Hina Khan, Grace Glace, Jessica M. Clement, Pier Vitale Nuzzo, Petros Grivas, Brett A. Schroeder, Tanios Bekaii-Saab, John M. Nakayama, Vasil Mico, Young Soo Rho, Chaim Miller, Amit Verma, Kaitlin M. Kelleher, Elwyn C. Cabebe, William A. Wood, Elizabeth J. Davis, Anne H. Angevine, Cristiano Ferrario, Shaveta Vinayak, Jerome J. Graber, Monika Joshi, Danielle A. Shafer, Mary M. Pasquinelli, Mark Bonnen, Shirish M. Gadgeel, Balazs Halmos, Lucy L. Wang, Dawn L. Hershman, Sana Z. Mahmood, Dimpy P. Shah, Maryam B. Lustberg, Albert C. Yeh, Eric H. Bernicker, Mitrianna Streckfuss, Leslie A. Fecher, Clement Pillainayagam, Karen Stauffer, Gayathri Nagaraj, Dimitrios Farmakiotis, Elizabeth Marie Wulff-Burchfield, Chintan Shah, Sibel Blau, Ryan H. Nguyen, Lane R. Rosen, Robert L. Rice, Mark E. Dailey, Melanie J. Clark, Goetz Kloecker, Alicia K. Morgans, Cameron Rink, Umit Topaloglu, Mark A. Fiala, Saif I. Alimohamed, Gary K. Schwartz, Jessica Yasmine Islam, Bertrand Routy, James L. Chen, Oscar K. Serrano, Chinmay Jani, Shuchi Gulati, K.M. Lo, Alokkumar Jha, Anthony P. Gulati, Lori J. Rosenstein, Roy S. Herbst, Matthias Weiss, Justin Shaya, Philip E. Lammers, Irene S. Yu, Syed A. Ahmad, Salma K. Jabbour, Erin A. Gillaspie, Irma Hoyo-Ulloa, Jordan Kharofa, Jean M. Connors, Daniel Mundt, Christopher R. Friese, Ryan C. Lynch, Mansi R. Shah, Howard Zaren, M. Wasif Saif, Gerald Gantt, Lawrence E. Feldman, Jian Campian, Daniel Y. Reuben, Sanjay G. Revankar, Merry Jennifer Markham, Melissa Smits, Patricia LoRusso, Thorvardur R. Halfdanarson, Christine Pilar, Eric B. Durbin, Blanche Mavromatis, Yu Shyr, Jaymin M. Patel, Candice Schwartz, Ang Li, Antonio Giordano, Amit Kulkarni, Joerg Rathmann, Harry Menon, Amro Elshoury, Mahir Khan, Theresa M. Carducci, Susan Halabi, Sumit A. Shah, Jeremy L. Warner, Mehmet Asim Bilen, Kerry L. Reynolds, Michael A. Thompson, Ahmad Daher, Lidia Schapira, Eneida R. Nemecek, Sanjay Mishra, Jamie Stratton, Karen Vega-Luna, Tyler Masters, Corrie A. Painter, Archana Ajmera, Jorge A. Garcia, Wenxin Xu, Christopher Lemmon, and Jeanna Knoble

Subjects
0301 basic medicine, Cancer Research, Quality management, MEDLINE, 03 medical and health sciences, COVID-19 Testing, 0302 clinical medicine, Neoplasms, Pandemic, medicine, Electronic Health Records, Humans, Protocol (science), SARS-CoV-2, business.industry, Corporate governance, COVID-19, Cancer, Cell Biology, medicine.disease, Quality Improvement, Data Accuracy, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Scale (social sciences), Commentary, Business, Medical emergency, Quality assurance
Abstract

When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.

Published
2020
Full Text
View/download PDF

15. Mitochondria in Focus: Targeting the Cell-Death Mechanism

Author

De Vitto, H, Palorini, R, Votta, G, Chiaradonna, F Humberto De Vitto, Juan P. Valencia, James A. Radosevich Neal D. Hammer Mollie K. Rojas, Juel Chowdhury, Khatja Batool, Zane Deliu, Abdallah Oweidi Sarah G. Fitzpatrick, Sara C. Gordon Ben A. Croker, James A. Rickard, Inbar Shlomovitz, Arshed Al-Obeidi, Akshay A. D’Cruz, Motti Gerzic Ebro Esin Yoruke, Ugur Gezer Marco Beauséjour, Ariane Boutin, Pierre H. Vachon Leopold Eckhart Julie Alagha, Sulaiman Alshaar, Zane Deliu Maryam Khalili M. V. Skulachev, V.P. Skulachev Amalia M. Dolga, Sina Oppermann, Maren Richter, Birgit Hofrat, Sandra Neitemeier, Anja Jelinek, Gotham Ganjam, Carsten Culmsee Kate E. Lawlor, Stephanie Conos, James E. Vince Mollie K. Rojas, Chintan C. Gandhi, Lawrence E. Feldman Latin Mehta Chandi Charan Mandal Manikanda Raja, Juel Chowdhury Takuya Tamura, Hitoshi Okazawa Latham M. Malaiyandi, Lawrence A. Potempa, Nicholas Marschalk, Paiboon Jungsuwadee, Kirk E. Dineley Jamuna A. Baia, Ravishankar Rai V. Raquel De Souza, Lais Costa Ayub, Kenneth Yip, Radosevich, JA, Chiaradonna, F, De Vitto, H, Palorini, R, Votta, G, Chiaradonna, F Humberto De Vitto, Juan P. Valencia, James A. Radosevich Neal D. Hammer Mollie K. Rojas, Juel Chowdhury, Khatja Batool, Zane Deliu, Abdallah Oweidi Sarah G. Fitzpatrick, Sara C. Gordon Ben A. Croker, James A. Rickard, Inbar Shlomovitz, Arshed Al-Obeidi, Akshay A. D’Cruz, Motti Gerzic Ebro Esin Yoruke, Ugur Gezer Marco Beauséjour, Ariane Boutin, Pierre H. Vachon Leopold Eckhart Julie Alagha, Sulaiman Alshaar, Zane Deliu Maryam Khalili M. V. Skulachev, V.P. Skulachev Amalia M. Dolga, Sina Oppermann, Maren Richter, Birgit Hofrat, Sandra Neitemeier, Anja Jelinek, Gotham Ganjam, Carsten Culmsee Kate E. Lawlor, Stephanie Conos, James E. Vince Mollie K. Rojas, Chintan C. Gandhi, Lawrence E. Feldman Latin Mehta Chandi Charan Mandal Manikanda Raja, Juel Chowdhury Takuya Tamura, Hitoshi Okazawa Latham M. Malaiyandi, Lawrence A. Potempa, Nicholas Marschalk, Paiboon Jungsuwadee, Kirk E. Dineley Jamuna A. Baia, Ravishankar Rai V. Raquel De Souza, Lais Costa Ayub, Kenneth Yip, Radosevich, JA, and Chiaradonna, F

Abstract

An understanding of the mechanism of apoptosis has received a substantial amount of interest over the past decades. It is evident from many works that mitochondria play a pivotal role in keeping cell homeostasis in both physiological and pathological conditions. The ability of mitochondria to reprogram cell metabolism is a key function to cell life and death. Therefore, recent advances in mitochondrial bioenergetics have yielded underlying knowledge for basic biology and applied biology, particularly providing crucial insights in therapeutic strategies. A detailed scenario of full apoptosis biology exceeds the scope of this current chapter and has been covered elsewhere in the book (i.e., first and third chapters). In line with this, we discuss the role of mitochondrial morphology, mitochondrial bioenergetics, and cell metabolism into the context of cellular life‐or‐death decision, addressing how the contribution made by many apoptosis pathways has deepened our understanding of human diseases, especially for cancer and neurodegenerative diseases

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results